EP1225912A4 - A method of prophylaxis and treatment - Google Patents

A method of prophylaxis and treatment

Info

Publication number
EP1225912A4
EP1225912A4 EP00972430A EP00972430A EP1225912A4 EP 1225912 A4 EP1225912 A4 EP 1225912A4 EP 00972430 A EP00972430 A EP 00972430A EP 00972430 A EP00972430 A EP 00972430A EP 1225912 A4 EP1225912 A4 EP 1225912A4
Authority
EP
European Patent Office
Prior art keywords
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00972430A
Other languages
German (de)
French (fr)
Other versions
EP1225912A1 (en
Inventor
Leonard C Harrison
Arno Hanninen
Nathan R Martinez
David Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ3627A external-priority patent/AUPQ362799A0/en
Priority claimed from AUPQ4347A external-priority patent/AUPQ434799A0/en
Priority claimed from AUPQ7621A external-priority patent/AUPQ762100A0/en
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of EP1225912A1 publication Critical patent/EP1225912A1/en
Publication of EP1225912A4 publication Critical patent/EP1225912A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00972430A 1999-10-22 2000-10-20 A method of prophylaxis and treatment Withdrawn EP1225912A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AUPQ3627A AUPQ362799A0 (en) 1999-10-22 1999-10-22 A method of prophylaxis and treatment
AUPQ362799 1999-10-22
AUPQ4347A AUPQ434799A0 (en) 1999-11-26 1999-11-26 A method of propylaxis and treatment - II
AUPQ434799 1999-11-26
AUPQ7621A AUPQ762100A0 (en) 2000-05-19 2000-05-19 A method of prophylaxis and treatment - III
AUPQ762199 2000-05-19
PCT/AU2000/001299 WO2001030378A1 (en) 1999-10-22 2000-10-20 A method of prophylaxis and treatment

Publications (2)

Publication Number Publication Date
EP1225912A1 EP1225912A1 (en) 2002-07-31
EP1225912A4 true EP1225912A4 (en) 2004-09-29

Family

ID=27158188

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00972430A Withdrawn EP1225912A4 (en) 1999-10-22 2000-10-20 A method of prophylaxis and treatment

Country Status (4)

Country Link
EP (1) EP1225912A4 (en)
JP (1) JP2003512435A (en)
CA (1) CA2387652A1 (en)
WO (1) WO2001030378A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006833A1 (en) * 2013-07-19 2015-01-22 St. Vincent's Institute Of Medical Research A method for treating type 1 diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026218A1 (en) * 1995-02-20 1996-08-29 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530178A (en) * 1991-05-29 1996-06-25 The Ontario Cancer Institute Mutant mouse lacking CD8 surface marker
WO1997046573A1 (en) * 1996-06-07 1997-12-11 The University Of Virginia Patent Foundation Method of inhibiting antigen processing, chimeric proteins reflecting this method, and methods of expressing those proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026218A1 (en) * 1995-02-20 1996-08-29 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BALASA B ET AL: "CD40 LIGAND-CD40 INTERACTIONS ARE NECESSARY FOR THE INITIATION OF INSULITIS AND DIABETES IN NONOBESE DIABETIC MICE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 159, no. 9, 1 November 1997 (1997-11-01), pages 4620 - 4627, XP001180168, ISSN: 0022-1767 *
BIANCONE LUIGI ET AL: "Distinct regulatory roles of lymphocyte costimulatory pathways on T helper type 2-mediated autoimmune disease", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, no. 4, 1996, pages 1473 - 1481, XP002284659, ISSN: 0022-1007 *
FALK K ET AL: "ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 351, no. 6324, 23 May 1991 (1991-05-23), pages 290 - 296, XP000310533, ISSN: 0028-0836 *
FOEHLES J ET AL: "HUMAN PRO INSULIN 5. SYNTHESIS OF A PROTECTED PEPTIDE FRAGMENT CORRESPONDING TO THE SEQUENCE 24-45 OF THE PRO HORMONE", HOPPE-SEYLER'S ZEITSCHRIFT FUER PHYSIOLOGISCHE CHEMIE, vol. 361, no. 6, 1980, pages 849 - 856, XP009032231, ISSN: 0018-4888 *
GAIRIN J E ET AL: "DESIGN OF HIGH-AFFINITY MAJOR HISTOCOMPATIBILITY COMPLEX-SPECIFIC ANTAGONIST PEPTIDES THAT INHIBIT CYTOTOXIC T-LYMPHOCYTE ACTIVITY: IMPLICATIONS FOR CONTROL OF VIRAL DISEASE", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 11, 1 November 1992 (1992-11-01), pages 6755 - 6762, XP000560304, ISSN: 0022-538X *
HANNINEN A: "Prevention of autoimmune type 1 diabetes via mucosal tolerance: Is mucosal autoantigen administration as safe and effective as it should?", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 52, no. 3, September 2000 (2000-09-01), pages 217 - 225, XP002284663, ISSN: 0300-9475 *
HANNINEN ARNO ET AL: "Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity", JOURNAL OF CLINICAL INVESTIGATION, vol. 109, no. 2, January 2002 (2002-01-01), pages 261 - 267, XP002284664, ISSN: 0021-9738 *
HARRISON L C ET AL: "AEROSOL INSULIN INDUCES REGULATORY CD8 GAMMADELTA T CELLS THAT PREVENT MURINE INSULIN-DEPENDENT DIABETES", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 6, no. 184, December 1996 (1996-12-01), pages 2167 - 2174, XP001070421, ISSN: 0022-1007 *
HOWARD LAURENCE M ET AL: "Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis", JOURNAL OF CLINICAL INVESTIGATION, vol. 103, no. 2, January 1999 (1999-01-01), pages 281 - 290, XP002284660, ISSN: 0021-9738 *
KONIARAS C ET AL: "Inhibition of naive class I-restricted T cells by altered peptide ligands", IMMUNOLOGY AND CELL BIOLOGY, vol. 77, no. 4, August 1999 (1999-08-01), pages 318 - 323, XP002284662, ISSN: 0818-9641 *
MARTINEZ N R ET AL: "DISABLING AN INTEGRAL CTL EPITOPE ALLOWS SUPPRESSION OF AUTOIMMUNE DIABETES BY INTRANASAL PROINSULIN PEPTIDE", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 111, no. 9, May 2003 (2003-05-01), pages 1365 - 1371, XP001168667, ISSN: 0021-9738 *
MARTINEZ N R ET AL: "Mucosa-mediated tolerance to native and modified proinsulin peptide in the non-obese diabetic mouse", IMMUNOLOGY LETTERS, vol. 69, no. 1, 15 June 1999 (1999-06-15), 10th International Congress of Mucosal Imunology;Amsterdam, Netherlands; June 27-July 1, 1999, pages 84, XP002284661, ISSN: 0165-2478 *
RUDY G ET AL: "SIMILAR PEPTIDES FROM TW BETA CELL AUTOANTIGENS, PROINSULIN AND GLUTAMIC ACID DECARBOXYLASE, STIMULATE T CELLS OF INDIVIDUALS AT RISK FOR INSULIN-DEPENDENT DIABETES", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, 1 September 1995 (1995-09-01), pages 625 - 633, XP000607204, ISSN: 1076-1551 *
See also references of WO0130378A1 *
TIAN JIDE ET AL: "Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, no. 4, 1996, pages 1561 - 1567, XP009032068, ISSN: 0022-1007 *
VON HERRATH M G ET AL: "In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 NOV 1998, vol. 161, no. 9, 1 November 1998 (1998-11-01), pages 5087 - 5096, XP000919064, ISSN: 0022-1767 *
YANAIHARA N ET AL: "SYNTHESES OF C PEPTIDES AND HUMAN PRO INSULIN", DIABETES, vol. 27, no. SUPPL 1, 1978, pages 149 - 160, XP009032235, ISSN: 0012-1797 *

Also Published As

Publication number Publication date
WO2001030378A1 (en) 2001-05-03
EP1225912A1 (en) 2002-07-31
JP2003512435A (en) 2003-04-02
CA2387652A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
HU0001471D0 (en) New method of treatment
EP1191941A4 (en) A method for the prophylaxis and/or treatment of medical disorders
GB2371011B (en) Method of forming a treated fiber and a treated fiber formed therefrom
EP1113808A4 (en) A method of treatment and agents useful for same
EP1284746A4 (en) A method of treatment and prophylaxis
SG99857A1 (en) A method of treatment and prophylaxis
AUPQ582400A0 (en) A method of treatment and agents for use therein
EP1267911A4 (en) A method of treatment
EP1225912A4 (en) A method of prophylaxis and treatment
EP1189630A4 (en) A method of prophylaxis and treatment and agents useful for same
EP0956039A4 (en) A method of treatment and prophylaxis
GB9812941D0 (en) Method of treatment
AUPR626001A0 (en) A method of treatment and/or prophylaxis
AUPQ362799A0 (en) A method of prophylaxis and treatment
AUPQ022099A0 (en) A method of prophylaxis and treatment
AUPP937799A0 (en) A method of prophylaxis and treatment
AUPQ199999A0 (en) A method of treatment and agents useful for same
GB0016445D0 (en) A method of treatment and/or prophylaxis
AUPP776298A0 (en) A method of treatment and prophylaxis
AU4385200A (en) A method of prophylaxis and treatment and agents useful therefor
AUPQ021999A0 (en) A method of prophylaxis and treatment and agents useful therefor
AUPP748898A0 (en) A method of prophylaxis and treatment
AUPQ856500A0 (en) A method of treatment and/or prophylaxis
AU781936C (en) A method of treatment and agents useful for same
AUPQ656500A0 (en) A method of treatment and agents for same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/28 A

Ipc: 7A 61K 38/19 B

Ipc: 7C 07K 16/28 B

Ipc: 7A 61P 3/10 B

Ipc: 7A 61P 37/02 B

Ipc: 7A 61K 39/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040812

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: A METHOD OF PROPHYLAXIS AND TREATMENT OF AUTOIMMUNE DISEASES, IN PARTICULAR OF DIABETES

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090723